NMT Medical CardioSeal
This article was originally published in The Gray Sheet
Executive Summary
Septal occluder cardiac implant gains FDA humanitarian use designation approval for closing fenestrated Fontan procedures. Designed to close holes in the heart, the device is in clinical trials for "broader approval," NMT says. The HUD allows treatment of up to 4,000 patients per year
You may also be interested in...
NMT Medical CardioSeal
Septal occluder cardiac implant receives second FDA humanitarian use designation approval, expanding use to include closure of ventricular septal defects that cannot be closed using standard surgical approaches, the firm announces Sept. 28. On Sept. 9, NMT announced FDA approval for humanitarian use (under 4,000 patients) of the device to close fenestrated Fontan procedures (1"The Gray Sheet" Sept. 13, In Brief)
Rochester Medical FemSoft Incontinence Insert Among FY 1999's 33 PMAs
FDA approval of Rochester Medical's FemSoft insert for female stress urinary incontinence on Sept. 30, the final day of the federal government's fiscal year, apparently put the agency's total number of approved, original premarket approval applications for the year at 33, down from 42 in 1998 and 46 in 1997.
NMT Medical CardioSeal
Septal occluder cardiac implant receives second FDA humanitarian use designation approval, expanding use to include closure of ventricular septal defects that cannot be closed using standard surgical approaches, the firm announces Sept. 28. On Sept. 9, NMT announced FDA approval for humanitarian use (under 4,000 patients) of the device to close fenestrated Fontan procedures (1"The Gray Sheet" Sept. 13, In Brief)